Les systèmes colloïdaux de délivrance de médicaments ont-ils aidé à répondre aux espérances thérapeutiques des découvertes de biotechnologie?

Translated title of the contribution: Colloid drug delivery systems: A response to therapeutic expectations arising from biotechnological advances?

D. Goldstein, G. Lambert, Fr Puisieux, S. Benita*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

New and fascinating advances in biotechnology have open new perspectives since the use of monoclonal antibodies for therapeutic application, particularly cancer, has been approved. Over the last two decades, numerous research teams have demonstrated that the progression of cancer is often associated with an over-expression of one or several proteins, called tumor antigens. In order to target tumors specifically, researchers have tried to couple monoclonal antibodies with colloid vectors such as liposomes, nanoparticles, and emulsions containing cytotoxic compounds. Use of these conjugated vector-antibody systems for the treatment of cancer is designed to target cancerous cells while sparing healthy cells. We present here a discussion on the synergy between biotechnology and modern molecular pharmotechnology, opening new horizons for therapy.

Translated title of the contributionColloid drug delivery systems: A response to therapeutic expectations arising from biotechnological advances?
Original languageFrench
Pages (from-to)90-104
Number of pages15
JournalAnnales Pharmaceutiques Francaises
Volume63
Issue number1
DOIs
StatePublished - Jan 2005

Keywords

  • Anticancer chemotherapy
  • Biotechnology
  • Colloidal vectors
  • Molecular pharmatechnology

Fingerprint

Dive into the research topics of 'Colloid drug delivery systems: A response to therapeutic expectations arising from biotechnological advances?'. Together they form a unique fingerprint.

Cite this